glycine has been researched along with Huntington Disease in 13 studies
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Complexin II is reduced in Huntington's disease (HD) patients and in the R6/2 mouse model of HD." | 1.33 | A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. ( Brose, N; Gibson, HE; Jones, S; Morton, AJ; Reim, K, 2005) |
| "Mean glycine concentration was significantly increased (P < or = 0." | 1.30 | Huntington's disease: N-methyl-D-aspartate receptor coagonist glycine is increased in platelets. ( Lange, HW; Reilmann, R; Rolf, LH, 1997) |
| "Huntington's disease is a dominantly inherited, progressive neurodegenerative disorder causing marked pathology in the basal ganglia." | 1.28 | Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. ( Dure, LS; Penney, JB; Young, AB, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| McGarry, A | 1 |
| Gaughan, J | 1 |
| Hackmyer, C | 1 |
| Lovett, J | 1 |
| Khadeer, M | 1 |
| Shaikh, H | 1 |
| Pradhan, B | 1 |
| Ferraro, TN | 1 |
| Wainer, IW | 1 |
| Moaddel, R | 1 |
| Wang, JQ | 1 |
| Chen, Q | 2 |
| Wang, X | 1 |
| Wang, QC | 1 |
| Wang, Y | 1 |
| Cheng, HP | 1 |
| Guo, C | 1 |
| Sun, Q | 1 |
| Tang, TS | 1 |
| Squitieri, F | 1 |
| Cannella, M | 1 |
| Simonelli, M | 1 |
| Rite, I | 1 |
| Machado, A | 1 |
| Cano, J | 1 |
| Venero, JL | 1 |
| Gibson, HE | 1 |
| Reim, K | 1 |
| Brose, N | 1 |
| Morton, AJ | 1 |
| Jones, S | 1 |
| Reynolds, GP | 1 |
| Pearson, SJ | 1 |
| Hutson, PH | 1 |
| Reilmann, R | 1 |
| Rolf, LH | 1 |
| Lange, HW | 1 |
| Calabresi, P | 1 |
| Centonze, D | 1 |
| Pisani, A | 1 |
| Bernardi, G | 1 |
| Tourian, A | 1 |
| Hung, W | 1 |
| Dure, LS | 1 |
| Young, AB | 1 |
| Penney, JB | 1 |
| Vamvakides, A | 1 |
| Bonilla, E | 1 |
| Prasad, AL | 1 |
| Arrieta, A | 1 |
| Simanyi, M | 1 |
| Gerstenbrand, F | 1 |
| Gründig, E | 1 |
| Schedl, R | 1 |
| Weiss, H | 1 |
1 review available for glycine and Huntington Disease
| Article | Year |
|---|---|
[A hypothesis for pharmacologic research on GABAergic approaches in Huntington chorea].
Topics: Animals; Central Nervous System; gamma-Aminobutyric Acid; Glutamates; Glycine; Humans; Huntington Di | 1989 |
12 other studies available for glycine and Huntington Disease
| Article | Year |
|---|---|
Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot study.
Topics: Adult; Arginine; Biomarkers; Creatine; Cross-Sectional Studies; Disability Evaluation; Female; Glyci | 2020 |
Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease.
Topics: Animals; Bradykinin; Calcium; Calcium Channels; Calcium Signaling; DNA Damage; DNA, Mitochondrial; E | 2013 |
CAG mutation effect on rate of progression in Huntington's disease.
Topics: Age of Onset; Alanine; Cysteine; Disease Progression; DNA Mutational Analysis; Female; Follow-Up Stu | 2002 |
Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Corpus Striatum; Cyclopropanes; Denerva | 2005 |
A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse.
Topics: 2-Amino-5-phosphonovalerate; Adaptor Proteins, Vesicular Transport; Age Factors; Animals; Anticonvul | 2005 |
Deficit of [3H]L-689,560 binding to the glycine site of the glutamate/NMDA receptor in the brain in Huntington's disease.
Topics: Adult; Aged; Aminoquinolines; Binding Sites; Cadaver; Caudate Nucleus; Female; Frontal Lobe; Glycine | 1994 |
Huntington's disease: N-methyl-D-aspartate receptor coagonist glycine is increased in platelets.
Topics: Adult; Blood Platelets; Female; Glycine; Humans; Huntington Disease; Male; Middle Aged; Models, Neur | 1997 |
Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington's disease.
Topics: Animals; Brain Ischemia; Calcium Channels; Cell Communication; Cells, Cultured; Cerebral Cortex; Cho | 1999 |
Glucosamine dependence of Huntington's chorea fibroblasts in culture.
Topics: Asparagine; Fibroblasts; Glucosamine; Glutamine; Glycine; Huntington Disease | 1976 |
Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease.
Topics: Adolescent; Adult; Age Factors; Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Bind | 1991 |
Huntington's disease: studies on brain free amino acids.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids; Aspartic Acid; Brain; Female; gamma-Aminobutyric Acid; | 1988 |
[Effect of administration of amino acids, especially of L-DOPA and -methyldopa, on the composition of cerebrospinal fluid in extrapyramidal syndromes. 3. Alterations of cerebrospinal fluid in patients with Huntington's chorea after -methyldopa or L-DOPA
Topics: Adult; Aged; Alanine Transaminase; Asparagine; Aspartic Acid; Child; Dihydroxyphenylalanine; Female; | 1973 |